PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Celecoxib - Pain & inflammation - musculoskeletal

PAD Profile : Celecoxib - Pain & inflammation - musculoskeletal Important

Keywords :
COXIIs, Coxib, cyclo-oxygenase-2, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, PNMP
Brand Names Include :
Celebrex
Important Information :
Preferred COX II inhibitor for licensed indications

Traffic Light Status

Status 1 of 1.

Status :
Green
Preferred
Formulations :
  • Capsules
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date
Safety Information
01 July 2022

Committee Recommendations

Date
Committee Name
Narrative
03 July 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee recommends celecoxib as a treatment option for the treatment of pain and inflammation in line with the product licence*.

Celecoxib will be considered as GREEN on the traffic light system and is the preferred COX II inhibitor for use where a COX II inhibitor is indicated.

*Licenced for: Osteoarthritis, Rheumatoid Arthritis & Ankylosing Spondylitis

The branded product, Celebrex, is considered BLACK. Prescribe generically for this indication.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.01. Non-steroidal anti-inflammatory drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More